Although insulin stimulates protein synthesis and inhibits protein breakdown in skeletal muscle in vitro, the actual contribution of these actions to its anabolic effects in man remains unknown. Using the forearm perfusion method together with systemic infusion of L-[ring-2,6-3H phenylalanine and L-I1-'4Cjleucine, we measured steady state amino acid exchange kinetics across muscle in seven normal males before and in response to a 2-h intraarterial infusion of insulin. Postabsorptively, the muscle disposal (Rd) of phenylalanine (43±5 nmol/min per 100 ml forearm) and leucine (113±13) was exceeded by the concomitant muscle production (R.) of these amino acids (57±5 and 126±9 nmol/ min per dl, respectively), resulting in their net release from the forearm (-14±4 and -13±5 nmol/min per dl, respectively). In response to forearm hyperinsulinemia (124±11 MU/ml), the net balance of phenylalanine and leucine became positive (9±3 and 61±8 nmol/min per dl, respectively (P < 0.005 vs. basal). Despite the marked increase in net balance, the tissue Rd for both phenylalanine (42±2) and leucine (124±9) was unchanged from baseline, while R. was markedly suppressed (to 33±5 and 63±9 nmol/min per dl, respectively, P < 0.01). Since phenylalanine is not metabolized in muscle (i.e., its only fates are incorporation into or release from protein) these results strongly suggest that in normal man, physiologic elevations in insulin promote net muscle protein anabolism primarily by inhibiting protein breakdown, rather than by stimulating protein synthesis.
Introduction
In vitro studies have firmly established the ability of insulin to stimulate protein synthesis and inhibit protein degradation in skeletal muscle (1) (2) (3) (4) (5) (6) (7) (8) (9) . In man, insulin has been shown to promote a more positive net balance of amino acids across muscle (10), but whether this anabolic effect is mediated primarily by an alteration in protein synthesis, breakdown, or both remains unknown. In the present study we addressed this question using a new isotopic technique for assessing protein synthesis and breakdown in human forearm Muscle.
Subjects and experimental design. Seven healthy adult male volunteers age 18-29 yr were studied after a 10-12-h overnight fast. All weighed within 15% of ideal body weight (Metropolitan Life Insurance Tables,  1983) . Skeletal muscle amino acid exchange kinetics were measured using a combination ofthe conventional forearm muscle balance method ( 11) with the systemic infusion of radiolabeled phenylalanine and leucine. Catheters were introduced percutaneously into the brachial artery and into an ipsilateral deep forearm vein (retrograde) draining muscle (12) . Through a contralateral arm vein, subjects received a 4-h primed-continuous infusion of L-[ring-2,6-3H]phenylalanine (" 32 ,1Ci, 0.64 MCi/ min) (8.1±0.4 X lI0 dpm/min) and L-[I-'4C]leucine , 0.14 MCi/ min) (2.3±0.2 X l10 dpm/min). After. a 2-h basal tracer equilibration period, during which patency of the arterial catheter was maintained by a slow infusion ofnormal saline (0.3 ml/min), insulin (diluted in a solution of normal saline and albumin) was infused directly into the brachial artery at 0.05 mU/kg per min for 2 h, using the same volume infusion rate. Arterial and venous blood samples were obtained at -30, -15, and 0 min during the basal state, and at 80, 100, and 120 min during the insulin infusion, when all measurements exhibited steady state conditions. A pediatric sphygmomanometer cufflwas inflated about the wrist to 200 mmHg for 3 min before and during each sampling interval to exclude blood flow to the hand. Forearm blood flow (13) was measured at each sampling interval from the dilution of indocyanine green dye (ICG)' infused intraarterially for 5 min. Forearm volume was determined by water displacement.
Each subject gave informed, written consent before participating in the study, which was approved by the Human Investigations Committee of Yale University.
Analytical methods. Blood glucose concentration was measured by the glucose oxidase method, and plasma insulin concentration was measured with a double antibody radioimmunoassay (14) . The concentration of ICG dye in infusate and plasma were measured spectrophotometrically at 810 nm. Blood phenylalanine and leucine concentrations were measured in sulfesalicylic acid extracts of blood using an automated ion exchange chromatographic technique (D-500, Dionex, Sunnyvale, CA). For the determination of L-[ring-2,6-3H]phenylalanine and L-[ I-'4C]leucine radioactivity, duplicate aliquots of each sulfosalicylic acid extract and tracer infusate were placed on a Dowex 50W cation exchange column (Bio-Rad Laboratories, Richmond, CA); radioactivity was quantitated in the eluted amino acid fraction using a dual channel liquid scintillation counter with external standard correction (Packard Instruments, Downers Grove, IL). Recovery ofamino acid standards from the Dowex column averaged 97±2%. More than 98% of the _4C-radioactivity and 95% of the 3H-radioactivity in circulating amino acids were in the leucine and phenylalanine peaks, respectively, after separation by ion exchange chromatography.
Calculations. The net forearm balances of glucose and amino acids were calculated as
where A and V are the arterial and venous blood concentrations, respectively, and F is the forearm blood flow. The net muscle balance of phenylalanine and leucine represents the difference between two simultaneously ongoing processes, namely, the rate of tissue amino acid disposal (Rd), and the rate of tissue amino acid production (R.); that is, Net balance = Rd -R.
The tissue disposal of blood-borne phenylalanine or leucine can be calculated from the measured fractional extraction (E) of its tracer as
where E is the arteriovenous difference in tracer radioactivity divided by arterial tracer radioactivity (all in dpm/ml). Muscle production of new (unlabeled) amino acid can then be calculated from Eq. 1-3: R.=EX [A] XF-([A) [V] )XF, which reduces to the expression: (4) where SAa and SA, denote the specific activity (dpm/nmol) of phenylalanine or leucine in artery and vein, respectively. Expressing Eq. 4 conceptually, the measured dilution across the tissue oftracer specific activity is used to calculate the contribution to the total venous amino acid efflux ,MU/ml, P < 0.001) for 2 h. Systemic insulin concentrations measured in a contralateral arm vein showed no detectable increase during the study (6±1 ueU/ml). Glucose disposal in the insulin-perfused forearm rose fourfold (1.15±0.13 to 4.67±0.67 ,grnol/min per 100 ml, P < 0.005); arterial (systemic) blood glucose concentrations showed a slight decline during the study (4.6±0.1 mM, basal, to 4.3±0.1 mM, P < 0.05). Forearm blood flow showed a small, but significant 25% increase during insulin infusion, (3.2±0.2 to 4.0±0.4 ml/min per dl, P < 0.05), consistent with previous work suggesting that hyperinsulinemia may di rectly augment muscle blood flow (20) . In keeping with the neg ligible change in systemic insulin levels, arterial concentration of phenylalanine and leucine (Table I) , as well as total acidiP and neutral amino acids (2,208±112 jsmol/liter, basal, vs 2126±93, insulin, P = NS), were not altered by the local insulir infusion. Similarly, no significant changes were observed in the whole body flux rates of circulating phenylalanine (38±2 Mmolj min) and leucine (93±6 ,mol/min) during local hyperinsulinemia (P = NS vs. basal). During insulin infusion, forearm muscle balance of both phenylalanine and leucine reversed from a basal net output to a net uptake (to 9±3 and 61±8 nmol/min per 100 ml, respectively, P < 0.005) (Fig. 2) . Despite the very marked increase in net uptake of these amino acids from blood, the tracer data demonstrate that for both phenylalanine and leucine the actual tissue disposal rates (Rd) of circulating amino acid (42±2 and For leucine, Rd reflects not only its incorporation into protein, but also its tissue disposal via intracellular metabolism (transamination, oxidation). It should be noted that the observed ratio of leucine Rd to phenylalanine Rd in the present study averaged 2.6 to 2.9 in the postabsorptive and insulinized states, which is similar to the reported ratio of 2.4 for these amino acids in skeletal muscle protein (19). This observation suggests that in skeletal muscle, as in the whole body (19), incorporation into protein accounts for the bulk of total leucine turnover. Thus, while the kinetics offorearm muscle leucine exchange cannot be regarded as a pure measure of tissue protein turnover, any major change in rates oftissue protein synthesis or breakdown, as reflected by phenylalanine Rd and Ra, should generally be reflected, at least in a directional sense, by parallel changes in leucine kinetics.
The present study demonstrates the effect ofinsulin on forearm muscle phenylalanine and leucine kinetics. As shown in Fig. 2 , the entire effect of insulin to promote a positive muscle balance ofthese amino acids could be accounted for by marked inhibition of cold amino acid release into venous blood. Forearm muscle disposal of both phenylalanine and leucine showed no significant change from baseline. These observations using two independent amino acids suggest that in normal man hyperinsulinemia ofthis magnitude and duration may not substantially stimulate protein synthesis above basal rates. Rather, the potent net anabolic action of insulin on muscle in this setting appears to be mediated primarily by a marked reduction in the rate of protein breakdown.
Inferences about tissue protein physiology based on circulating amino acid kinetic measurements must always be approached with caution. A number ofmethodologic assumptions and limitations must be explicitly acknowledged. Key among these, of course, is the assumption that phenylalanine is not metabolized in skeletal muscle, a view that is strongly supported by in vitro animal studies (2, (15) (16) (17) , but for which the evidence in man remains largely indirect. An assumption implicit in our method, as in all in vivo amino acid turnover techniques, is that there is no label recycling, i.e., that tracer incorporated into protein is not released back into the free amino acid pool (thereby lowering flux estimates) during the period of observation. In whole body turnover studies, such recycling has been shown to become quantitatively significant during prolonged (e.g., 18 h) amino acid tracer infusions in man, presumably reflecting release oftracer from short-lived body proteins (21). In the present study, given the short total duration of tracer infusion (4 h), the very brief (2 h) period that separated the basal and experimental measurements, and the relatively slow turnover of muscle as compared with other body proteins (19), the contribution of label recycling to our comparative forearm measurements should be negligible. Empirical support for this view is provided by the stability of the whole body flux estimates (reflecting muscle as well as other, more rapidly turning over proteins) measured over this same time period. Finally, the dependence of all tissue balance calculations on the measurement of blood flow should be emphasized, as the difficulties intrinsic to this measurement, such as the potential for incomplete mixing of dye (13), will obviously limit the ultimate accuracy oftissue kinetic estimates. Such considerations underscore some of the quantitative limitations of the present method.
Perhaps the most important uncertainty involved in extrapolating circulating amino acid kinetics to tissue protein turnover arises from our inability to directly measure the amino acid specific activity in the actual precursor pool for protein synthesis, namely, aminoacyl-tRNA. To the extent that the specific activity of phenylalanyl-tRNA may be lower than that of arterial phenylalanine (due to dilution by internally recycled phenylalanine), the present calculations, based on blood amino acid kinetics, must be regarded as minimum estimates of the rate of tissue protein turnover. This uncertainty regarding precursor pool specific activity is not unique to the present method but is shared by all amino acid turnover techniques used to assess body protein metabolism in man (19). In the context of whole body leucine turnover studies, one approach to this problem has involved the measurement of circulating alpha-ketoisocaproate (KIC) specific activity as an index ofmixed intracellular leucine specific activity (22) . Although such an approach does not provide a direct index ofthe true precursor pool for protein synthesis (aminoacyl-tRNA specific activity is generally higher than that of the mixed intracellular pool [23] [24] [25] [26] ), it does provide a valuable means for monitoring changes in intracellular tracer dilution occurring in the course of an experiment. In the context of the present method, an analogous approach takes advantage of the fact that the specific activity of venous phenylalanine (SAy), having been diluted by phenylalanine released from the intracellular pool, should be closer to the mixed intracellular specific activity than are the arterial measurements, and changes in intracellular phe-nylalanine dilution should be reflected by changes in SA,. Thus, the increase in SA, observed during insulin infusion (Fig. 1 , Table I ) is consistent with a rise in intracellular specific activity due to inhibition of protein breakdown by insulin. Calculating Ra and Rd using SA, rather than SAa as the reference pool then provides an alternative means for estimating phenylalanine kinetics which should be responsive to changes in intracellular dilution. With this change Eq. 4 becomes Ra = F X [A] X (SAa/ SA, -1), which is analogous to the equation used by others (2, 16) to assess protein degradation in isolated perfused muscle preparations. Applying this approach to the present data yields higher absolute estimates for rates ofphenylalanine release from protein (82±9 nmol/min per 100 ml, basal), but a virtually identical fractional suppression (by 46%) in response to insulin (to 44+7, P < 0.02). Phenylalanine incorporation into protein estimated in this fashion (F X [dpm/mla -dpm/ml,]/SA,) again showed no significant change, and if anything a slight fall, in response to insulin (68±9 to 53±4 nmol/min per 100 ml, P = NS). Although it remains unclear whether SAa or SA, provides the better absolute estimate of phenylalanyl-tRNA specific activity, application of either model to the present observations leads to the same conclusion, namely, that hyperinsulinemia suppressed tissue proteolysis but did not measurably stimulate protein synthesis.
These results appear to be at variance with a wealth of in vitro data demonstrating that insulin not only inhibits protein degradation (1-6), but also stimulates protein synthesis in skeletal muscle (1) (2) (3) (4) (5) (6) (7) (8) (9) . While we cannot definitively exclude a small increase in synthesis in response to insulin (type II error), our results do provide evidence that the major anabolic effect of hyperinsulinemia in vivo is exerted at the level of protein degradation. This in vivo response appears to differ from that of muscle studied in vitro, where synthesis, rather than degradation, is generally found to be the more insulin-sensitive process (2, 3, 6) .
Direct extrapolation of the in vitro effects of insulin to the in vivo setting of physiologic hyperinsulinemia must be undertaken with caution. In fact, the discrepancy between the present study results and those obtained in vitro may actually be more apparent than real. Investigators studying both perfused (2) and isolated (8) muscle preparations have noted little or no effect of insulin to stimulate protein synthesis early in the incubation period, when synthetic rates are highest and presumably closest to those present in vivo. It is only during subsequent hours, when synthesis rates decline in muscles maintained without insulin, that a rapid stimulatory effect of added insulin is readily demonstrable (2, 8) . Interestingly, muscles from insulin-deficient diabetic animals, which exhibit depressed rates of protein synthesis in vitro, do respond to insulin during the initial period of perfusion (4, 7) . In keeping with these observations, in vivo studies have readily shown an impairment in muscle protein synthesis in diabetic animals, which is at least partially reversible with insulin (27) (28) (29) (30) , while stimulation of synthesis by insulin in nondiabetic animals has proved far more difficult to demonstrate (28) . These considerations, coupled with the present study results, raise the possibility that the stimulatory effect of insulin on protein synthesis may be manifest in vivo at normal postabsorptive insulin concentrations. Suppression of degradation, in contrast, may require higher insulin concentrations for its full expression in vivo, as is the case in vitro (2) In summary, the results of the present study provide strong evidence that inhibition of protein breakdown, rather than stimulation of synthesis, is the major mechanism whereby acute physiologic elevations in insulin promote net muscle protein anabolism in normal man. The measurement of forearm phenylalanine kinetics provides a unique, nondestructive in vivo technique for assessing rates ofprotein synthesis and breakdown in human skeletal muscle.
